中国医药
中國醫藥
중국의약
CHINA MEDICINE
2014年
12期
1735-1737
,共3页
张兰芳%赵文萍%冯惠平%陈彦霞%贾辛未%陈春红%王占启%赵淑君%王艳飞
張蘭芳%趙文萍%馮惠平%陳彥霞%賈辛未%陳春紅%王佔啟%趙淑君%王豔飛
장란방%조문평%풍혜평%진언하%가신미%진춘홍%왕점계%조숙군%왕염비
急性心肌梗死%瑞舒伐他汀%心肌营养素1
急性心肌梗死%瑞舒伐他汀%心肌營養素1
급성심기경사%서서벌타정%심기영양소1
Acute myocardial infarction%Rosuvastatin%Cardiotrophin-1
目的 探讨不同剂量瑞舒伐他汀对急性心肌梗死(AMI)患者血清心肌营养素1(CT-1)水平及心功能的影响.方法 将112例AMI患者按照用药剂量分为2组,瑞舒伐他汀常规剂量治疗组(常规剂量组,60例)患者在常规应用阿司匹林、氯吡格雷、硝酸盐类、β受体阻滞剂等药物治疗基础上加服瑞舒伐他汀10 mg/d;瑞舒伐他汀强化剂量治疗组(强化剂量组,52例)患者在常规药物治疗基础上加服瑞舒伐他汀20 mg/d.另完全随机选取40例体检正常者作为对照组.对照组于AMI患者用药前,常规剂量组、强化剂量组分别于用药前及用药后4周空腹静脉采血检测CT-1水平并检查超声心动图指标,包括左心室舒张末期内径(LVEDD)、左心室收缩末期内径(LVESD)和左心室射血分数(LVEF).结果 用药前常规剂量组、强化剂量组CT-1水平、LVEDD及LVESD[(333 ±53) ng/L、(339 ±51)ng/L,(59.5±6.4)mm、(58.2±7.6) mm,(40.7 ±7.4) mm、(40.4 ±6.2) mm]明显高于对照组[(42.6±11.2) ng/L,(38.2±1.8)mm,(30.2±1.2)mm],LVEF[(41.1±6.8)％、(41.4±7.2)％]明显低于对照组[(58.2±0.9)％],用药后4周,CT-1水平、LVEDD及LVESD[(152 ±28) ng/L、(108± 19)ng/L,(52.1 ±6.1)mm、(46.4±4.9)mm,(34.5 ±4.6)mm、(30.9±4.2)mm]明显降低,LVEF明显升高[(47.5±6.1)％、(52.8±6.2)％],差异均有统计学意义(P＜0.05).与常规剂量组比较,强化剂量组上述指标改善更为明显(P＜0.05).结论 瑞舒伐他汀可有效降低患者CT-1水平,抑制心室重塑,改善患者心功能.
目的 探討不同劑量瑞舒伐他汀對急性心肌梗死(AMI)患者血清心肌營養素1(CT-1)水平及心功能的影響.方法 將112例AMI患者按照用藥劑量分為2組,瑞舒伐他汀常規劑量治療組(常規劑量組,60例)患者在常規應用阿司匹林、氯吡格雷、硝痠鹽類、β受體阻滯劑等藥物治療基礎上加服瑞舒伐他汀10 mg/d;瑞舒伐他汀彊化劑量治療組(彊化劑量組,52例)患者在常規藥物治療基礎上加服瑞舒伐他汀20 mg/d.另完全隨機選取40例體檢正常者作為對照組.對照組于AMI患者用藥前,常規劑量組、彊化劑量組分彆于用藥前及用藥後4週空腹靜脈採血檢測CT-1水平併檢查超聲心動圖指標,包括左心室舒張末期內徑(LVEDD)、左心室收縮末期內徑(LVESD)和左心室射血分數(LVEF).結果 用藥前常規劑量組、彊化劑量組CT-1水平、LVEDD及LVESD[(333 ±53) ng/L、(339 ±51)ng/L,(59.5±6.4)mm、(58.2±7.6) mm,(40.7 ±7.4) mm、(40.4 ±6.2) mm]明顯高于對照組[(42.6±11.2) ng/L,(38.2±1.8)mm,(30.2±1.2)mm],LVEF[(41.1±6.8)％、(41.4±7.2)％]明顯低于對照組[(58.2±0.9)％],用藥後4週,CT-1水平、LVEDD及LVESD[(152 ±28) ng/L、(108± 19)ng/L,(52.1 ±6.1)mm、(46.4±4.9)mm,(34.5 ±4.6)mm、(30.9±4.2)mm]明顯降低,LVEF明顯升高[(47.5±6.1)％、(52.8±6.2)％],差異均有統計學意義(P＜0.05).與常規劑量組比較,彊化劑量組上述指標改善更為明顯(P＜0.05).結論 瑞舒伐他汀可有效降低患者CT-1水平,抑製心室重塑,改善患者心功能.
목적 탐토불동제량서서벌타정대급성심기경사(AMI)환자혈청심기영양소1(CT-1)수평급심공능적영향.방법 장112례AMI환자안조용약제량분위2조,서서벌타정상규제량치료조(상규제량조,60례)환자재상규응용아사필림、록필격뢰、초산염류、β수체조체제등약물치료기출상가복서서벌타정10 mg/d;서서벌타정강화제량치료조(강화제량조,52례)환자재상규약물치료기출상가복서서벌타정20 mg/d.령완전수궤선취40례체검정상자작위대조조.대조조우AMI환자용약전,상규제량조、강화제량조분별우용약전급용약후4주공복정맥채혈검측CT-1수평병검사초성심동도지표,포괄좌심실서장말기내경(LVEDD)、좌심실수축말기내경(LVESD)화좌심실사혈분수(LVEF).결과 용약전상규제량조、강화제량조CT-1수평、LVEDD급LVESD[(333 ±53) ng/L、(339 ±51)ng/L,(59.5±6.4)mm、(58.2±7.6) mm,(40.7 ±7.4) mm、(40.4 ±6.2) mm]명현고우대조조[(42.6±11.2) ng/L,(38.2±1.8)mm,(30.2±1.2)mm],LVEF[(41.1±6.8)％、(41.4±7.2)％]명현저우대조조[(58.2±0.9)％],용약후4주,CT-1수평、LVEDD급LVESD[(152 ±28) ng/L、(108± 19)ng/L,(52.1 ±6.1)mm、(46.4±4.9)mm,(34.5 ±4.6)mm、(30.9±4.2)mm]명현강저,LVEF명현승고[(47.5±6.1)％、(52.8±6.2)％],차이균유통계학의의(P＜0.05).여상규제량조비교,강화제량조상술지표개선경위명현(P＜0.05).결론 서서벌타정가유효강저환자CT-1수평,억제심실중소,개선환자심공능.
Objective To investigate the effects of different doses of rosuvastatin on serum concentration of cardiotrophin-1 (CT-1) and cardiac function in acute myocardial infarction (AMI) patients.Methods One hundred and twelve AMI patients were randomly divided into two groups.The conventional dose rosuvastatin group (60 cases) took 10 mg/d rosuvastatin in addition to routine therapy (such as aspirin clopidogrel nitrate and β-blocker) ; the strengthening dose group(52 cases) took 20mg/d rosuvastatin in addition to routine therapy.40 cases of normal physical examination were randomly selected as the control group.The levels of CT-1,left ventricular enddiastolic diameter(LVEDD),left ventricular end-systolic dimension(LVESD) and ejection fraction(EF) were all measured in three groups before and after 4 weeks treatment.Results Before treatment,the levels of CT-1,LVEDD and LVESD in the conventional dose group and the strengthening dose group [(333 ± 53) ng/L,(339 ± 51) ng/L ; (59.5 ± 6.4) mm,(58.2 ± 7.6) mm ; (40.7 ± 7.4) mm,(40.4 ± 6.2) mm] were significantly higher than those in the control group [(42.6 ± 11.2) ng/L,(38.2 ± 1.8) mm,(30.2 ± 1.2) mm] (P ＜ 0.05) ; the levels of EF[(41.1 ± 6.8)％,(41.4 ± 7.2)％] were significantly lower than those in the control group[(58.2 ± 0.9) ％] (P ＜ 0.05).After 4 weeks later,the levels of CT-1,LVEDD and LVESD were all decreased significantly [(152±28) ng/L,(108± 19)ng/L;(52.1 ±6.1) mm,(46.4 ±4.9)mm;(34.5 ±4.6)mm,(30.9 ±4.2)mm] ; the levels of EF were increased[(47.5 ± 6.1) ％,(52.8 ± 6.2) ％].Conclusion Rosuvastatin can inhibit ventricular remodeling and improve cardiac function and long term prognosis.
